Table I.
Clinical studies associated with ALK inhibitors.
| Clinical study | Drug | mPFS (month) | ORR (%) |
|---|---|---|---|
| PROFILE 1001 (35) | Crizotinib | 9.7 | 60.8 |
| PROFILE 1005 (36) | Crizotinib | 8.4 | 54.0 |
| PROFILE 1007 (37) | Crizotinib | 7.7 | 65.0 |
| PROFILE 1014 (38) | Crizotinib | 10.9 | 74.0 |
| ASCEND-1 (39) | Ceritinib | 18.4 | 72.0 |
| ASCEND-2 (40) | Ceritinib | 5.7 | 38.6 |
| ASCEND-4 (41) | Ceritinib | 16.6 | 72.5 |
| J-ALEX (42) | Alectinib | 34.1 | 92.0 |
| ALEX (43,44) | Alectinib | 34.8 | 82.9 |
| ALTA-1L (45) | Brigatinib | 24.0 | 71.0 |
| B7461001 (46) | Lorlatinib | 9.6 | 46.0 |
ALK, anaplastic lymphoma kinase; mPFS, median progression-free survival; ORR, objective response rate.